{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:03:57Z","timestamp":1769317437851,"version":"3.49.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11864-020-00779-z","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T15:04:10Z","timestamp":1596812650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-5267","authenticated-orcid":false,"suffix":"III","given":"Roy E","family":"Strowd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"issue":"1","key":"779_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005;141(1):71\u20134.","journal-title":"Arch Dermatol"},{"key":"779_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp-2018-318538","volume":"89","author":"DG Evans","year":"2018","unstructured":"Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89:1\u20135. https:\/\/doi.org\/10.1136\/jnnp-2018-318538.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"779_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cas.13116","volume":"108","author":"O Hino","year":"2017","unstructured":"Hino O, Kobayashi T. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex. Cancer Sci. 2017;108(1):5\u201311. https:\/\/doi.org\/10.1111\/cas.13116.","journal-title":"Cancer Sci"},{"key":"779_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10897-007-9101-8","volume":"16","author":"HB Radtke","year":"2007","unstructured":"Radtke HB, Sebold CD, Allison C, Haidle JL, Schneider G. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16:387\u2013407. https:\/\/doi.org\/10.1007\/s10897-007-9101-8.","journal-title":"J Genet Couns"},{"issue":"15","key":"779_CR5","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.18632\/oncotarget.2194","volume":"5","author":"Y-S Yap","year":"2014","unstructured":"Yap Y-S, McPherson JR, Ong C-K, et al. The NF1 gene revisited - from bench to bedside. Oncotarget. 2014;5(15):5873\u201392. https:\/\/doi.org\/10.18632\/oncotarget.2194.","journal-title":"Oncotarget"},{"issue":"2","key":"779_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81\u20138. https:\/\/doi.org\/10.1136\/jmg.2006.045906.","journal-title":"J Med Genet"},{"issue":"3 Pt 1","key":"779_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1542\/peds.105.3.608","volume":"105","author":"K DeBella","year":"2000","unstructured":"DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105(3 Pt 1):608\u201314.","journal-title":"Pediatrics."},{"key":"779_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DGR Evans","year":"2009","unstructured":"Evans DGR. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"552","key":"779_CR9","doi-asserted-by":"publisher","first-page":"eaau1165","DOI":"10.1126\/scisignal.aau1165","volume":"11","author":"AL Elaimy","year":"2018","unstructured":"Elaimy AL, Mercurio AM. Convergence of VEGF and YAP\/TAZ signaling: implications for angiogenesis and cancer biology. Sci Signal. 2018;11(552):eaau1165. https:\/\/doi.org\/10.1126\/scisignal.aau1165.","journal-title":"Sci Signal"},{"issue":"2","key":"779_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/archneur.1994.00540140115021","volume":"51","author":"The Consensus Development Panel","year":"1994","unstructured":"The Consensus Development Panel. National Institutes of Health consensus development conference statement on acoustic neuroma, December 11-13, 1991 The Consensus Development Panel. Arch Neurol. 1994;51(2):201\u20137.","journal-title":"Arch Neurol"},{"issue":"10","key":"779_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","volume":"17","author":"VL Merker","year":"2012","unstructured":"Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012;17(10):1317\u201322. https:\/\/doi.org\/10.1634\/theoncologist.2012-0162.","journal-title":"Oncologist."},{"issue":"9","key":"779_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 2012;14(9):1163\u201370. https:\/\/doi.org\/10.1093\/neuonc\/nos146.","journal-title":"Neuro-Oncology"},{"issue":"3","key":"779_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/PAS.0000000000000110","volume":"38","author":"TJM Hulsebos","year":"2014","unstructured":"Hulsebos TJM, Kenter S, Siebers-Renelt U, Hans V, Wesseling P, Flucke U. SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis. Am J Surg Pathol. 2014;38(3):421\u20135. https:\/\/doi.org\/10.1097\/PAS.0000000000000110.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"779_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10048-009-0204-2","volume":"11","author":"C Bacci","year":"2010","unstructured":"Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, et al. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics. 2010;11(1):73\u201380. https:\/\/doi.org\/10.1007\/s10048-009-0204-2.","journal-title":"Neurogenetics."},{"issue":"5569","key":"779_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.1068452","volume":"296","author":"Y Zhu","year":"2002","unstructured":"Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296(5569):920\u20132. https:\/\/doi.org\/10.1126\/science.1068452.","journal-title":"Science."},{"issue":"5","key":"779_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/neuonc\/nou004","volume":"16","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, et al. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro-Oncology. 2014;16(5):707\u201318. https:\/\/doi.org\/10.1093\/neuonc\/nou004.","journal-title":"Neuro-Oncology"},{"issue":"9","key":"779_CR17","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","volume":"61","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61(9):1598\u2013602. https:\/\/doi.org\/10.1002\/pbc.25041.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"779_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/pbc.24873","volume":"61","author":"B Weiss","year":"2014","unstructured":"Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014;61(6):982\u20136. https:\/\/doi.org\/10.1002\/pbc.24873.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"779_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B Weiss","year":"2015","unstructured":"Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro-Oncology. 2015;17(4):596\u2013603. https:\/\/doi.org\/10.1093\/neuonc\/nou235.","journal-title":"Neuro-Oncology"},{"issue":"2","key":"779_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/now158","volume":"19","author":"RI Jakacki","year":"2017","unstructured":"Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-Oncology. 2017;19(2):289\u201397. https:\/\/doi.org\/10.1093\/neuonc\/now158.","journal-title":"Neuro-Oncology"},{"issue":"12","key":"779_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13(12):1218\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(12)70414-X.","journal-title":"Lancet Oncol"},{"issue":"26","key":"779_CR22","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"\u2022\u2022 Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1605943 This study describes results of the phase 1 study of selumetinib for treating progressive plexiform neurofibromas in patients with NF1 demonstrating a dramatic 71% response rate.","journal-title":"N Engl J Med"},{"key":"779_CR23","doi-asserted-by":"publisher","unstructured":"\u2022\u2022Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/nejmoa1912735 This study describes results of the phase 2 study of selumetinib for treating symptomatic, inoperable plexiform neurofibromas in patients with NF1 demonstrating a 70% radiographic response and 68% clinical improvement rate.","DOI":"10.1056\/nejmoa1912735"},{"issue":"2","key":"779_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ajmg.a.35720","volume":"161","author":"C Cesaretti","year":"2013","unstructured":"Cesaretti C, Melloni G, Quagliarini D, Fogliani R, Zaina B, Bedeschi MF, et al. Neurofibromatosis type 1 and pregnancy: maternal complications and attitudes about prenatal diagnosis. Am J Med Genet Part A. 2013;161(2):386\u20138. https:\/\/doi.org\/10.1002\/ajmg.a.35720.","journal-title":"Am J Med Genet Part A"},{"issue":"1","key":"779_CR25","doi-asserted-by":"publisher","first-page":"46.e1","DOI":"10.1016\/j.ajog.2013.03.029","volume":"209","author":"AR Terry","year":"2013","unstructured":"Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR. Neurofibromatosis type 1 and pregnancy complications: a population-based study. Am J Obstet Gynecol. 2013;209(1):46.e1\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2013.03.029.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"779_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jbspin.2012.07.010","volume":"80","author":"C Schnabel","year":"2013","unstructured":"Schnabel C, Jett K, Friedman JM, Frieling I, Kruse HP, Mautner V. Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Jt Bone Spine. 2013;80(3):315\u20139. https:\/\/doi.org\/10.1016\/j.jbspin.2012.07.010.","journal-title":"Jt Bone Spine"},{"issue":"3\u20134","key":"779_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1515\/jpem.2011.092","volume":"24","author":"DA Stevenson","year":"2011","unstructured":"Stevenson DA, Viskochil DH, Carey JC, Sheng X, Murray M, Moyer-Mileur L, et al. Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2011;24(3\u20134):169\u201374. https:\/\/doi.org\/10.1515\/jpem.2011.092.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"779_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00403-011-1191-3","volume":"304","author":"L Petramala","year":"2012","unstructured":"Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G, et al. Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res. 2012;304(4):325\u201331. https:\/\/doi.org\/10.1007\/s00403-011-1191-3.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"779_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/jmg.2006.041095","volume":"43","author":"M Lammert","year":"2006","unstructured":"Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D, et al. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet. 2006;43(10):810\u20133. https:\/\/doi.org\/10.1136\/jmg.2006.041095.","journal-title":"J Med Genet"},{"key":"779_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/6162182","volume":"2016","author":"D Tovmassian","year":"2016","unstructured":"Tovmassian D, Abdul Razak M, London K. The role of [18F]FDG-PET\/CT in predicting malignant transformation of plexiform neurofibromas in neurofibromatosis-1. Int J Surg Oncol. 2016;2016:1\u20137. https:\/\/doi.org\/10.1155\/2016\/6162182.","journal-title":"Int J Surg Oncol"},{"issue":"11","key":"779_CR31","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1212\/wnl.0000000000008092","volume":"93","author":"S Ahlawat","year":"2019","unstructured":"Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology. 2019;93(11):e1076\u201384. https:\/\/doi.org\/10.1212\/wnl.0000000000008092.","journal-title":"Neurology."},{"issue":"1","key":"779_CR32","doi-asserted-by":"publisher","first-page":"e1982","DOI":"10.1097\/GOX.0000000000001982","volume":"7","author":"LA Taylor","year":"2019","unstructured":"Taylor LA, Lewis VL. Neurofibromatosis type 1: Review of cutaneous and subcutaneous tumor treatment on quality of life. Plast Reconstr Surg - Glob Open. 2019;7(1):e1982. https:\/\/doi.org\/10.1097\/GOX.0000000000001982.","journal-title":"Plast Reconstr Surg - Glob Open"},{"issue":"4","key":"779_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","volume":"18","author":"JM Slopis","year":"2018","unstructured":"Slopis JM, Arevalo O, Bell CS, Hebert AA, Northrup H, Riascos RF, et al. Treatment of disfiguring cutaneous lesions in neurofibromatosis-1 with everolimus: a phase II, open-label, single-arm trial. Drugs R D. 2018;18(4):295\u2013302. https:\/\/doi.org\/10.1007\/s40268-018-0248-6.","journal-title":"Drugs R D"},{"issue":"5","key":"779_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archderm.1993.01680260047004","volume":"129","author":"VM Riccardi","year":"1993","unstructured":"Riccardi VM. A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol. 1993;129(5):577\u201381 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8481017. Accessed February 29, 2020.","journal-title":"Arch Dermatol"},{"issue":"12","key":"779_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41416-018-0073-2","volume":"118","author":"RJ Allaway","year":"2018","unstructured":"Allaway RJ, Gosline SJC, La Rosa S, et al. Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br J Cancer. 2018;118(12):1539\u201348. https:\/\/doi.org\/10.1038\/s41416-018-0073-2.","journal-title":"Br J Cancer"},{"issue":"1","key":"779_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/0008-5472.CAN-10-2732","volume":"71","author":"JL Nakamura","year":"2011","unstructured":"Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, et al. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res. 2011;71(1):106\u201315.","journal-title":"Cancer Res"},{"issue":"16","key":"779_CR37","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","volume":"24","author":"S Sharif","year":"2006","unstructured":"Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570\u20135. https:\/\/doi.org\/10.1200\/JCO.2005.03.8349.","journal-title":"J Clin Oncol"},{"key":"779_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3332\/ecancer.2018.862","volume":"12","author":"H Papalia","year":"2018","unstructured":"Papalia H, Audic F, Rivi\u00e8re GR, Verschuur A, Andr\u00e9 N. Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas. Ecancermedicalscience. 2018;12:862. https:\/\/doi.org\/10.3332\/ecancer.2018.862.","journal-title":"Ecancermedicalscience."},{"key":"779_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-020-03443-6","volume":"147","author":"V Esp\u00edrito Santo","year":"2020","unstructured":"Esp\u00edrito Santo V, Passos J, Nzwalo H, Carvalho I, Santos F, Martins C, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neuro-Oncol. 2020;147:1\u20135. https:\/\/doi.org\/10.1007\/s11060-020-03443-6.","journal-title":"J Neuro-Oncol"},{"issue":"10056","key":"779_CR40","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet (London, England). 2016;388(10056):2153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(16)31419-2.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"779_CR41","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1542\/peds.2013-1224","volume":"133","author":"C Hua","year":"2014","unstructured":"Hua C, Zehou O, Ducassou S, Minard-Colin V, Hamel-Teillac D, Wolkenstein P, et al. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas. Pediatrics. 2014;133(6):e1792\u20137. https:\/\/doi.org\/10.1542\/peds.2013-1224.","journal-title":"Pediatrics."},{"issue":"3","key":"779_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","volume":"139","author":"O Zehou","year":"2019","unstructured":"Zehou O, Ferkal S, Brugieres P, Barbarot S, Bastuji-Garin S, Combemale P, et al. Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial. J Invest Dermatol. 2019;139(3):718\u201320. https:\/\/doi.org\/10.1016\/j.jid.2018.09.016.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"779_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaapos.2009.11.020","volume":"14","author":"L Segal","year":"2010","unstructured":"Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS. 2010;14(2):155\u20138.","journal-title":"J AAPOS"},{"issue":"16","key":"779_CR44","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0000000000003881","volume":"88","author":"J Mahdi","year":"2017","unstructured":"Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, et al. A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology. 2017;88(16):1584\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000003881.","journal-title":"Neurology."},{"issue":"10","key":"779_CR45","first-page":"1963","volume":"22","author":"L Kornreich","year":"2001","unstructured":"Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen IJ, et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. Am J Neuroradiol. 2001;22(10):1963\u20139.","journal-title":"Am J Neuroradiol"},{"issue":"2","key":"779_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/08880018.2016.1155101","volume":"33","author":"D Doganis","year":"2016","unstructured":"Doganis D, Pourtsidis A, Tsakiris K, Baka M, Kouri A, Bouhoutsou D, et al. Optic pathway glioma in children: 10 years of experience in a single institution. Pediatr Hematol Oncol. 2016;33(2):102\u20138. https:\/\/doi.org\/10.3109\/08880018.2016.1155101.","journal-title":"Pediatr Hematol Oncol"},{"issue":"12","key":"779_CR47","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1212\/01.wnl.0000257095.33125.48","volume":"68","author":"NJ Ullrich","year":"2007","unstructured":"Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007;68(12):932\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000257095.33125.48.","journal-title":"Neurology."},{"issue":"12","key":"779_CR48","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/cncr.29987","volume":"122","author":"JL Ater","year":"2016","unstructured":"Ater JL, Xia C, Mazewski CM, Booth TN, Freyer DR, Packer RJ, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children\u2019s Oncology Group. Cancer. 2016;122(12):1928\u201336. https:\/\/doi.org\/10.1002\/cncr.29987.","journal-title":"Cancer."},{"issue":"23","key":"779_CR49","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1002\/cncr.29649","volume":"121","author":"AJ Dodgshun","year":"2015","unstructured":"Dodgshun AJ, Elder JE, Hansford JR, Sullivan MJ. Long-term visual outcome after chemotherapy for optic pathway glioma in children: site and age are strongly predictive. Cancer. 2015;121(23):4190\u20136. https:\/\/doi.org\/10.1002\/cncr.29649.","journal-title":"Cancer."},{"issue":"5","key":"779_CR50","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","volume":"11","author":"RJ Packer","year":"1993","unstructured":"Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11(5):850\u20136. https:\/\/doi.org\/10.1200\/JCO.1993.11.5.850.","journal-title":"J Clin Oncol"},{"issue":"13","key":"779_CR51","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1200\/JCO.2002.12.008","volume":"20","author":"S Gururangan","year":"2002","unstructured":"Gururangan S, Cavazos CM, Ashley D, Herndon JE II, Bruggers CS, Moghrabi A, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002;20(13):2951\u20138. https:\/\/doi.org\/10.1200\/JCO.2002.12.008.","journal-title":"J Clin Oncol"},{"issue":"29","key":"779_CR52","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","volume":"34","author":"A Lassaletta","year":"2016","unstructured":"Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, et al. Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study. J Clin Oncol. 2016;34(29):3537\u201343. https:\/\/doi.org\/10.1200\/JCO.2016.68.1585.","journal-title":"J Clin Oncol"},{"issue":"2","key":"779_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-014-1652-6","volume":"121","author":"AM Cappellano","year":"2015","unstructured":"Cappellano AM, Petrilli AS, da Silva NS, Silva FA, Paiva PM, Cavalheiro S, et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neuro-Oncol. 2015;121(2):405\u201312. https:\/\/doi.org\/10.1007\/s11060-014-1652-6.","journal-title":"J Neuro-Oncol"},{"issue":"suppl_2","key":"779_CR54","doi-asserted-by":"publisher","first-page":"i111","DOI":"10.1093\/neuonc\/noy059.374","volume":"20","author":"J Belsky","year":"2018","unstructured":"Belsky J, Graham R, Leonard J, et al. LGG-33. MEK-Inhibitor monotherapy to treat concurrent optic glioma and metastatic neuroblastoma in a patient with neurofibromatosis type 1 (NF1). Neuro-Oncology. 2018;20(suppl_2):i111. https:\/\/doi.org\/10.1093\/neuonc\/noy059.374.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"779_CR55","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","volume":"19","author":"S Perreault","year":"2019","unstructured":"\u2022\u2022 Perreault S, Larouche V, Tabori U, et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01. BMC Cancer. 2019;19(1):1250. https:\/\/doi.org\/10.1186\/s12885-019-6442-2 This study describes the study design for a phase II study evaluating the activity of trametinib (MEK inhibitor) for treating optic pathway and other low-grade gliomas in pediatric patients including children with NF1.","journal-title":"BMC Cancer"},{"issue":"10","key":"779_CR56","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology. 2014;16(10):1408\u201316. https:\/\/doi.org\/10.1093\/neuonc\/nou059.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"779_CR57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/brain\/awg016","volume":"126","author":"JS Guillamo","year":"2003","unstructured":"Guillamo JS, Cr\u00e9ange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126(1):152\u201360.","journal-title":"Brain."},{"issue":"6","key":"779_CR58","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/ajmg.a.37622","volume":"170","author":"RE Strowd","year":"2016","unstructured":"Strowd RE, Rodriguez FJ, Mclendon RE, et al. Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. Am J Med Genet Part A. 2016;170(6):1455\u201361. https:\/\/doi.org\/10.1002\/ajmg.a.37622.","journal-title":"Am J Med Genet Part A"},{"issue":"3","key":"779_CR59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/NEN.0b013e318165eb75","volume":"67","author":"FJ Rodriguez","year":"2008","unstructured":"Rodriguez FJ, Perry A, Gutmann DH, O'Neill BP, Leonard J, Bryant S, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008;67(3):240\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"14","key":"779_CR60","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol. 2016;34(14):1669\u201375. https:\/\/doi.org\/10.1200\/JCO.2015.64.3817.","journal-title":"J Clin Oncol"},{"issue":"35","key":"779_CR61","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"\u2022\u2022 Plotkin SR, Duda DG, Muzikansky A, et al. Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol. 2019;37(35):3446\u201354. https:\/\/doi.org\/10.1200\/JCO.19.01367 This study describes the results of a multicenter phase II study evaluating high-dose bevacizumab for NF2 patients with symptomatic vestibular schwannomas showing that high-dose bevacizumab led to favorable radiographic and hearing responses that were similar to prior lower dose regimens and indicating that responses were not as robust in children compared with adults.","journal-title":"J Clin Oncol"},{"issue":"4","key":"779_CR62","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358\u201367. https:\/\/doi.org\/10.1056\/NEJMoa0902579.","journal-title":"N Engl J Med"},{"issue":"6","key":"779_CR63","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, et al. Bevacizumab for progressive vestibular Schwannoma in neurofibromatosis type 2. Otol Neurotol. 2012;33(6):1046\u201352. https:\/\/doi.org\/10.1097\/MAO.0b013e31825e73f5.","journal-title":"Otol Neurotol"},{"key":"779_CR64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart A, Gaillard V, Baroncini M, Andr\u00e9 N, Vannier JP, Vinchon M, et al. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neuro-Oncol. 2015;124:229\u201336. https:\/\/doi.org\/10.1007\/s11060-015-1828-8.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"779_CR65","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuchi.2016.09.004","volume":"64","author":"S Goutagny","year":"2018","unstructured":"Goutagny S, Kalamarides M. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. Neurochirurgie. 2018;64(5):370\u20134. https:\/\/doi.org\/10.1016\/j.neuchi.2016.09.004.","journal-title":"Neurochirurgie."},{"issue":"11","key":"779_CR66","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3109\/00207454.2015.1092443","volume":"126","author":"MC Alanin","year":"2016","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 \u2013 a retrospective case series. Int J Neurosci. 2016;126(11):1002\u20136. https:\/\/doi.org\/10.3109\/00207454.2015.1092443.","journal-title":"Int J Neurosci"},{"issue":"4","key":"779_CR67","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/nop\/npv065","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurol Pract. 2016;3(4):281\u20139. https:\/\/doi.org\/10.1093\/nop\/npv065.","journal-title":"Neurol Pract"},{"issue":"3","key":"779_CR68","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0194599818809085","volume":"160","author":"P Sverak","year":"2019","unstructured":"Sverak P, Adams ME, Haines SJ, Levine SC, Nascene D, Sommer K, et al. Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities. Otolaryngol - Head Neck Surg (United States). 2019;160(3):526\u201332. https:\/\/doi.org\/10.1177\/0194599818809085.","journal-title":"Otolaryngol - Head Neck Surg (United States)"},{"issue":"2","key":"779_CR69","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 2014;16(2):292\u20137. https:\/\/doi.org\/10.1093\/neuonc\/not150.","journal-title":"Neuro-Oncology"},{"key":"779_CR70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neuro-Oncol. 2015;122:313\u201320. https:\/\/doi.org\/10.1007\/s11060-014-1710-0.","journal-title":"J Neuro-Oncol"},{"issue":"7","key":"779_CR71","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31(7):1135\u201343. https:\/\/doi.org\/10.1097\/MAO.0b013e3181eb328a.","journal-title":"Otol Neurotol"},{"issue":"1","key":"779_CR72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.54.1.71","volume":"54","author":"J Antinheimo","year":"2000","unstructured":"Antinheimo J, Sankila R, Carp\u00e9n O, Pukkala E, Sainio M, J\u00e4\u00e4skel\u00e4inen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54(1):71\u20136.","journal-title":"Neurology."},{"key":"779_CR73","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1200\/JCO.2016","volume":"35","author":"J Campian","year":"2017","unstructured":"Campian J, Gutmann DH. CNS tumors in Neurofibromatosis. J Clin Oncol. 2017;35:2378\u201385. https:\/\/doi.org\/10.1200\/JCO.2016.","journal-title":"J Clin Oncol"},{"issue":"1","key":"779_CR74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158 A","author":"JO Blakeley","year":"2012","unstructured":"\u2022\u2022 Blakeley JO, Evans DG, Adler J, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet Part A. 2012;158 A(1):24\u201341. https:\/\/doi.org\/10.1002\/ajmg.a.34359 This is an excellent review of consensus recommendations for managing patient with NF2.","journal-title":"Am J Med Genet Part A"},{"issue":"11","key":"779_CR75","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/00005537-200011000-00015","volume":"110","author":"DD Massick","year":"2000","unstructured":"Massick DD, Welling DB, Dodson EE, Scholfield M, Nagaraja HN, Schmalbrock P, et al. Tumor growth and audiometric change in vestibular schwannomas managed conservatively. Laryngoscope. 2000;110(11):1843\u20139. https:\/\/doi.org\/10.1097\/00005537-200011000-00015.","journal-title":"Laryngoscope."},{"issue":"5","key":"779_CR76","doi-asserted-by":"publisher","first-page":"345","DOI":"10.14639\/0392-100X-1093","volume":"36","author":"M Ruggieri","year":"2016","unstructured":"Ruggieri M, Pratic\u00f2 AD, Serra A, et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital. 2016;36(5):345\u201367. https:\/\/doi.org\/10.14639\/0392-100X-1093.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"779_CR77","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1212\/CPJ.0000000000000648","volume":"9","author":"A Shukla","year":"2019","unstructured":"Shukla A, Ba F-C, Hsu B, et al. Association between patient-reported outcomes and objective disease indices in people with NF2. Neurology Clinical Practice. 2019;9:322\u20139. https:\/\/doi.org\/10.1212\/CPJ.0000000000000648.","journal-title":"Neurology Clinical Practice"},{"issue":"4","key":"779_CR78","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmg.2005.036319","volume":"43","author":"DGR Evans","year":"2006","unstructured":"Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43(4):289\u201394.","journal-title":"J Med Genet"},{"issue":"3","key":"779_CR79","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ijrobp.2007.01.001","volume":"68","author":"R Chopra","year":"2007","unstructured":"Chopra R, Kondziolka D, Niranjan A, Lunsford LD, Flickinger JC. Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys. 2007;68(3):845\u201351. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.01.001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"779_CR80","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.wneu.2017.08.159","volume":"109","author":"LK Chung","year":"2018","unstructured":"Chung LK, Nguyen TP, Sheppard JP, Lagman C, Tenn S, Lee P, et al. A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas. World Neurosurg. 2018;109:47\u201358. https:\/\/doi.org\/10.1016\/j.wneu.2017.08.159.","journal-title":"World Neurosurg"},{"issue":"1","key":"779_CR81","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","volume":"131","author":"KA Morris","year":"2017","unstructured":"Morris KA, Golding JF, Blesing C, et al. Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. J Neuro-Oncol. 2017;131(1):117\u201324. https:\/\/doi.org\/10.1007\/s11060-016-2276-9.","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"779_CR82","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","volume":"144","author":"VM Lu","year":"2019","unstructured":"Lu VM, Ravindran K, Graffeo CS, Perry A, van Gompel JJ, Daniels DJ, et al. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes. J Neuro-Oncol. 2019;144(2):239\u201348. https:\/\/doi.org\/10.1007\/s11060-019-03234-8.","journal-title":"J Neuro-Oncol"},{"key":"779_CR83","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"3","author":"KM Slusarz","year":"2014","unstructured":"Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014;3:1197\u2013204. https:\/\/doi.org\/10.1007\/s00280-014-2456-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"779_CR84","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11060-016-2257-z","volume":"130","author":"B Birckhead","year":"2016","unstructured":"Birckhead B, Sio TT, Pollock BE, Link MJ, Laack NN. Gamma knife radiosurgery for neurofibromatosis type 2-associated meningiomas: a 22-year patient series. J Neuro-Oncol. 2016;130(3):553\u201360. https:\/\/doi.org\/10.1007\/s11060-016-2257-z.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"779_CR85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","volume":"14","author":"SR Plotkin","year":"2011","unstructured":"Plotkin SR, O\u2019Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients: clinical article. J Neurosurg Spine. 2011;14(4):543\u20137. https:\/\/doi.org\/10.3171\/2010.11.SPINE10350.","journal-title":"J Neurosurg Spine"},{"issue":"3","key":"779_CR86","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11060-017-2690-7","volume":"136","author":"M Kalamarides","year":"2018","unstructured":"Kalamarides M, Essayed W, Lejeune JP, Aboukais R, Sterkers O, Bernardeschi D, et al. Spinal ependymomas in NF2: a surgical disease? J Neuro-Oncol. 2018;136(3):605\u201311. https:\/\/doi.org\/10.1007\/s11060-017-2690-7.","journal-title":"J Neuro-Oncol"},{"issue":"21","key":"779_CR87","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1212\/WNL.0000000000000997","volume":"83","author":"J Blakeley","year":"2014","unstructured":"Blakeley J, Schreck KC, Evans DG, Korf BR, Zagzag D, Karajannis MA, et al. Clinical response to Bevacizumab in schwannomatosis. Neurology. 2014;83(21):1986\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000997.","journal-title":"Neurology."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00779-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00779-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00779-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T23:30:00Z","timestamp":1628292600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00779-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00779-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"7 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Roy E. Strowd serves as a consultant for Monteris Medical Inc., Novocure, and Nanobiotix; he receives an editorial stipend as Section Editor of the Resident and Fellow Section of Neurology(R) and has received research\/grant support from the American Academy of Neurology, American Society of Clinical Oncology, Southeastern Brain Tumor Foundation, and Jazz Pharmaceuticals; however, none of these is relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"81"}}